

## Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results.

**Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented:** *"We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are satisfied with the encouraging disease control rate achieved in late stage and heavily pretreated melanoma patients in the ATLAS-IT-05 study. Secondly, we recognize the large commercial potential that could be realized through the potential use of LTX-315 in basal cell carcinoma patients. After examining the reassuring data from the Phase II study presented by our partner Verrica Pharmaceuticals during this quarter, we very much look forward to the results of their entire Phase II study, which is expected to be completed during the first half of 2024. Adding to that, we have great expectations for the upcoming study where LTX-315 will be tested in earlier stage melanoma patients in the neoadjuvant NeoLIPA trial at Oslo University Hospital Radiumhospitalet during 2024."*

### Highlights from the third quarter 2023, and post-period events:

- ATLAS-IT-05 – Encouraging preliminary data presented at ESMO 2023:
  - Disease control rate of 43% and one patient achieving a partial response to date
  - There is evidence of tumor shrinkage in both injected and non-injected lesions
- Verrica Pharmaceuticals' Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (BCC):
  - Complete clearance was observed in lesions treated with the highest dose tested
  - Based on the stronger than expected activity observed in patients receiving LTX-315, Verrica has decided to accelerate the clinical development of LTX-315 and to complete the entire Phase II study in H1 2024
- Neoadjuvant study in earlier stage melanoma patients:
  - An investigator led Phase II study at Oslo University Hospital, Radiumhospitalet is being planned
  - The study protocol was presented at the 15<sup>th</sup> Nordic Melanoma Meeting, October 12<sup>th</sup>

## Key figures (unaudited):

### Profit and loss:

<i>Amounts in NOK thousands</i>	<i>Unaudited</i> Q3 2023	<i>Unaudited</i> Q3 2022	FY 2022
Total operating income	4,292	2,972	17,273
Total operating expenses	(22,936)	(20,915)	(82,968)
Loss from operations	(18,643)	(17,944)	(65,695)
Loss for the period	(18,248)	(11,148)	(56,006)

### Balance sheet:

<i>Amounts in NOK thousands</i>	<i>Unaudited</i> 30.09.2023	<i>Unaudited</i> 30.09.2022	31.12.2022
<b>Assets</b>			
Property, plant and equipment	127	137	124
Trade and other receivables	1,252	5,656	6,735
Short-term financial investments	32,609	49,909	50,606
Cash and cash equivalents	46,158	121,671	94,552
<b>Total assets</b>	<b>80,147</b>	<b>177,374</b>	<b>152,017</b>
<b>Shareholder's equity and liabilities</b>			
Total equity	68,952	163,883	135,126
Total liabilities	11,195	13,491	16,891
<b>Total equity and liabilities</b>	<b>80,147</b>	<b>177,374</b>	<b>152,017</b>

CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein will host a webcast for investors and analysts today at 14.30 CEST.

The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: <https://forms.office.com/e/N0xJzSx0Gg>

The presentation is now available at [www.lytixbiopharma.com](http://www.lytixbiopharma.com) in the Investors' section, and a recording of the presentation will be made available after the presentation.

### **For more information, please contact:**

Gjest Breistein, CFO

E-Mail: [gjest.breistein@lytixbiopharma.com](mailto:gjest.breistein@lytixbiopharma.com)

### **Optimum Strategic Communications**

Nick Bastin, Jonathan Edwards

E-mail: [lytix@optimumcomms.com](mailto:lytix@optimumcomms.com)

**Lytix in brief:**

Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient's immune system to fight cancer. The Company's technology is based on pioneering research in "host defense peptides" – nature's first line of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient's tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.